CP-31398 restores mutant p53 tumor suppressor function in vitro without affecting p53 homologs p63 and p73, and in vivo inhibiting UVB-induced skin carcinogenesis in mice. Stabilization of p53 inhibits ubiquitination without altering phosphorylation at Ser12 or Ser20 or MDM2 binding. Administration of this or similar compounds has the potential to enhance cytotoxic chemotherapy.
Product Details
| Alternative Name: | N'-[2-[2-(4-Methoxyphenyl)ethenyl]-4-quinazolinyl]-N,N-dimethyl-1,3-propanediamine dihydrochloride |
| |
| Formula: | C22H26N4O . 2HCl |
| |
| MW: | 435.4 |
| |
| Source: | Synthetic. |
| |
| CAS: | 259199-65-0 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | Yellow solid. |
| |
| Solubility: | Soluble in water (25mg/ml) or DMSO (5mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells: C. Huang, et al.; Cancer Biol. Ther.
8, 2186 (2009),
Abstract;
CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice: X. Tang, et al.; J. Clin. Invest.
117, 3753 (2007),
Abstract;
CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73: M.J. Demma, et al.; J. Biol. Chem.
279, 45887 (2004),
Abstract;
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding: W. Wang, et al.; Mol. Cell Biol.
23, 2171 (2003),
Abstract;
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells: T.M. Rippin, et al.; Oncogene
21, 2119 (2002),
Abstract;
